Across more than a million patient records, people taking semaglutide – a drug prescribed for type 2 diabetes – were between 40% and 70% less likely to receive a first-time Alzheimer’s diagnosis than patients on other diabetes medications. That finding, from a large 2024 analysis of nearly 1.1 million Americans with type 2 diabetes, didn’t come from a dementia trial. It came from researchers who were simply tracking what happened to blood sugar patients over three years.
That distinction matters. The study wasn’t designed to prevent cognitive decline. It was designed to manage glucose. The brain protection appeared to be a side effect, or possibly something much more deliberate, once scientists began examining why.
The connection between type 2 diabetes and dementia has been documented for decades, but the scale of it is still striking. People with type 2 diabetes face a 1.6-fold greater risk of developing dementia compared to their non-diabetic peers. The underlying reason has less to do with high blood sugar itself and more to do with what that blood sugar does to the brain over time. Research published in the journal Brain found a significant reduction in dementia risk among elderly metformin users – and the relationship was dose-dependent, meaning higher cumulative use corresponded to greater protection. Three separate classes of diabetes drugs now appear to share this brain-protective quality, through mechanisms that researchers are only beginning to untangle.
Why Diabetes Damages the Brain
A 2026 study in the European Journal of Pharmacology found that metformin use is associated with a reduced risk of dementia and all-cause mortality in older adults with type 2 diabetes. But to understand why diabetes drugs might shield the brain, it helps to understand what uncontrolled blood sugar does to it in the first place.
The brain is, among other things, a metabolic organ. It consumes roughly 20% of the body’s total energy despite making up only about 2% of its weight, and it depends almost entirely on glucose to function. When insulin resistance takes hold – the defining feature of type 2 diabetes, where cells stop responding properly to insulin – the brain’s ability to use that glucose begins to break down. Research published in Brain tracking elderly type 2 diabetes patients found that metformin users had an adjusted hazard ratio of 0.34 for dementia compared with non-users, representing a substantial protective effect.
A 2024 Lancet Standing Commission report estimated that nearly half of dementia cases may be preventable by addressing modifiable risk factors such as diabetes, obesity and high cholesterol. Researchers are now exploring whether drugs like semaglutide, which help treat several of those conditions, could also play a role in lowering dementia risk, but more research is needed.
Type 2 diabetes has long been linked to an increased risk of cognitive decline and dementia, although scientists are still working to understand exactly why. One leading theory is that insulin resistance, chronic inflammation and changes in how the brain uses glucose may gradually damage nerve cells and impair memory over time. The 2024 study published in Brain found that older adults with type 2 diabetes who took metformin had a significantly lower risk of developing dementia than non-users, even after researchers accounted for factors such as age, other medical conditions and medications. While the findings suggest metformin may have protective effects, the study does not prove that the drug directly prevents dementia.
Prior molecular research suggests that the increased dementia risk in diabetes may stem from elevated rates of atherosclerosis (hardening of the arteries), blood-brain barrier disturbances, insulin resistance, and augmented inflammation and oxidative stress. The landmark connection between these two diseases has led some researchers to informally call Alzheimer’s “type 3 diabetes,” though that framing remains debated in the field.
Metformin: The First Clue
Metformin is the most commonly prescribed oral diabetes drug in the world. It’s been in clinical use since the 1950s and remains the first-line therapy for type 2 diabetes in most countries. It works by reducing the liver’s production of glucose and improving the body’s sensitivity to insulin. Over time, data from large patient databases began showing that people on metformin seemed to develop dementia at lower rates than patients on other diabetes drugs.
A 2025 meta-analysis of over 3.4 million participants linked metformin use to a lower risk of dementia in patients with type 2 diabetes, and the data consistently held across different populations and study designs. Among 66,050 patients in the 2026 study published in the European Journal of Pharmacology, metformin use was associated with a 27% lower dementia risk, with a clear dose-response relationship – higher cumulative doses corresponded to greater risk reduction.
The mechanism behind this protection is still being studied, but several pathways have been proposed. Basic research shows that metformin can activate the AMPK pathway – a key regulator of cellular energy balance – and may improve insulin resistance in the brain, reduce neuronal cell death, and decrease oxidative stress and inflammation. These are exactly the processes that, when dysregulated, drive the build-up of the amyloid plaques and tau tangles characteristic of Alzheimer’s disease.
An ongoing 18-month, double-blind, placebo-controlled trial – the Metformin in Alzheimer’s Dementia Prevention study, led by researchers at Columbia University – is investigating protective effects of doses up to 2,000 mg per day, with results expected in 2027. If positive, that trial could shift how clinicians think about prescribing metformin – not only to manage blood sugar, but potentially to protect the aging brain.
GLP-1 Drugs: The Bigger Signal
The strongest and most recent evidence centers on a class of drugs called GLP-1 receptor agonists (GLP-1 RAs). These include semaglutide (sold as Ozempic and Wegovy), liraglutide (Victoza), and others. They work by mimicking a gut hormone that stimulates insulin release, slows digestion, and signals satiety to the brain. They’ve become enormously prominent in recent years for weight loss, but their effects on the brain have drawn equal attention in research circles.
Researchers analyzing health records from hundreds of thousands of people with diabetes found that those taking GLP-1 drugs developed dementia 40% to 70% less often than those taking other diabetes medicines. A large meta-analysis published in JAMA Neurology in 2025 – pooling 26 randomized trials and 164,531 participants – found that GLP-1 receptor agonists were associated with a statistically significant reduction in dementia risk.
A separate analysis of 100,000 US patients, conducted by researchers at the University of Oxford, found a 48% lower dementia risk in semaglutide users compared with those on sitagliptin, a different diabetes drug, over just one year. That’s a substantial difference for a timeframe that short.
The biology behind it is plausible. Semaglutide reduces inflammation throughout the body, improves insulin sensitivity, and enhances the brain’s ability to utilize glucose – and it may also prevent damage to blood vessels that causes dementia. In animal models, the effects were even more concrete. In a mouse model of Alzheimer’s disease, semaglutide improved brain glucose uptake, improved learning and memory, and decreased amyloid beta plaques and tau tangles.
The critical caveat: when Novo Nordisk ran large Phase 3 trials to test oral semaglutide directly in early Alzheimer’s patients – the EVOKE and EVOKE+ trials – the results were comprehensive in showing oral semaglutide’s lack of clinical efficacy for cognition or function in patients with early Alzheimer’s. The failure of oral semaglutide in the two EVOKE trials was hugely disappointing for the Alzheimer’s and neurodegenerative field. Researchers have been careful to separate two distinct questions, though: can these drugs treat established Alzheimer’s disease, and can they prevent dementia from developing in the first place? Despite the EVOKE failures, researchers reviewing the data did not believe this should mark the conclusion of investigations into GLP-1 drugs for Alzheimer’s – with particular interest in evaluating semaglutide as a preventive therapy, and in patients who have both Alzheimer’s and metabolic or vascular conditions.
The liraglutide trial data offered a partial glimmer. Researchers at the Alzheimer’s Association International Conference reported that liraglutide reduced cognitive decline by as much as 18% after one year of treatment compared to placebo in patients with mild Alzheimer’s disease – though that trial also failed its primary endpoint of cerebral glucose metabolism.
Read More: Diabetes Medicine Linked to Lower Dementia Risk, Scientists Find
SGLT2 Inhibitors: The Emerging Contender
A third class of diabetes drugs has entered the conversation with growing momentum. SGLT2 inhibitors – brand names include empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana) – work by causing the kidneys to excrete excess glucose in urine rather than reabsorbing it. They were originally developed for blood sugar control but have since demonstrated cardiovascular and kidney-protective effects that surprised even their developers.
Their brain-protective potential is now drawing similar scrutiny. A 2026 meta-analysis published in Endocrinology, Diabetes & Metabolism found that SGLT2 inhibitors were significantly associated with a reduced risk of incident dementia compared with DPP-4 inhibitors in patients with type 2 diabetes, including both Alzheimer’s and vascular dementia. A separate population-based cohort study found that SGLT2 inhibitor initiation was associated with a 14% lower dementia risk in the intention-to-treat analysis, with the as-treated analysis showing even greater risk reduction when patients continued using the drugs.
More recently, a July 2026 study published in JAMA Network Open found that SGLT2 inhibitor use was associated with a 39% lower risk of all-cause dementia in a study of over 112,000 older adults. That study focused on a population with psychiatric disorders – a group at particularly elevated dementia risk – but the biological mechanisms it identified are not specific to that group. The authors concluded that SGLT2 inhibitor use was associated with lower dementia risk and fewer psychiatric emergency visits, and they argued that the pattern strengthens the hypothesis of a shared metabolic vulnerability underlying both psychiatric and neurodegenerative diseases.
A 2026 network meta-analysis – which ranks drugs against each other rather than just against placebo – found that SGLT2 inhibitors were the most effective antidiabetic agent at reducing dementia risk, followed by GLP-1 receptor agonists. That ranking hasn’t yet shifted clinical practice, but it’s the kind of finding that tends to.
What the Numbers Add Up To
A 2024 analysis published in the American Journal of Preventive Medicine, drawing on data from 1,565,245 subjects across 16 studies, found that risks of dementia and Alzheimer’s disease were significantly lower in patients treated with metformin and SGLT2 inhibitors compared to other antidiabetic drugs. The lead investigator, Yeo Jin Choi, PharmD, PhD, of Kyung Hee University in Seoul, noted that the findings carry significant clinical implications for how diabetes management decisions are made. That’s a signal too consistent across too many datasets to dismiss.
What this research does not yet support is the idea that anyone should start taking diabetes drugs specifically to prevent dementia. None of these drugs – metformin, GLP-1 receptor agonists, or SGLT2 inhibitors – are currently approved for dementia prevention or treatment. They carry their own side effects and are prescribed for specific metabolic conditions under physician supervision.
What it does mean: if you or someone you know has type 2 diabetes and is managing it with medication, the choice of drug may matter beyond blood sugar control. The evidence suggests that metformin, GLP-1 receptor agonists, and SGLT2 inhibitors may all carry some degree of brain-protective effect compared with older alternatives like sulfonylureas or DPP-4 inhibitors. That’s a conversation worth having with a physician – not to add a medication, but to ensure the one already being taken is working as hard as the evidence suggests it can.
For people without diabetes, the most consistent finding across all of this research is that insulin resistance – the root metabolic dysfunction these drugs all target – appears to be a major driver of age-related cognitive decline. Diet quality, physical activity, and sleep, all of which affect insulin sensitivity, remain the most accessible and well-supported ways to protect the brain over time.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: Top 5 Metformin Side Effects and What You Need to Know